Literature DB >> 34737214

Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.

Danielle R Cook1, Melissa Kang2, Timothy D Martin3, Joseph A Galanko2, Gabriela H Loeza4, Dimitri G Trembath5,6, Verline Justilien7, Karen A Pickering8, David F Vincent8, Armin Jarosch9, Philipp Jurmeister9, Andrew M Waters5, Priya S Hibshman5,10, Andrew D Campbell8, Catriona A Ford8, Temitope O Keku2, Jen Jen Yeh3,5,11, Michael S Lee4,5, Adrienne D Cox3,5,12, Alan P Fields7, Robert S Sandler2, Owen J Sansom8,13, Christine Sers9,14,15, Antje Schaefer16,5, Channing J Der17,3,5,9.   

Abstract

ECT2 is an activator of RHO GTPases that is essential for cytokinesis. In addition, ECT2 was identified as an oncoprotein when expressed ectopically in NIH/3T3 fibroblasts. However, oncogenic activation of ECT2 resulted from N-terminal truncation, and such truncated ECT2 proteins have not been found in patients with cancer. In this study, we observed elevated expression of full-length ECT2 protein in preneoplastic colon adenomas, driven by increased ECT2 mRNA abundance and associated with APC tumor-suppressor loss. Elevated ECT2 levels were detected in the cytoplasm and nucleus of colorectal cancer tissue, suggesting cytoplasmic mislocalization as one mechanism of early oncogenic ECT2 activation. Importantly, elevated nuclear ECT2 correlated with poorly differentiated tumors, and a low cytoplasmic:nuclear ratio of ECT2 protein correlated with poor patient survival, suggesting that nuclear and cytoplasmic ECT2 play distinct roles in colorectal cancer. Depletion of ECT2 reduced anchorage-independent cancer cell growth and invasion independent of its function in cytokinesis, and loss of Ect2 extended survival in a Kras G12D Apc-null colon cancer mouse model. Expression of ECT2 variants with impaired nuclear localization or guanine nucleotide exchange catalytic activity failed to restore cancer cell growth or invasion, indicating that active, nuclear ECT2 is required to support tumor progression. Nuclear ECT2 promoted ribosomal DNA transcription and ribosome biogenesis in colorectal cancer. These results support a driver role for both cytoplasmic and nuclear ECT2 overexpression in colorectal cancer and emphasize the critical role of precise subcellular localization in dictating ECT2 function in neoplastic cells. SIGNIFICANCE: ECT2 overexpression and mislocalization support its role as a driver in colon cancer that is independent from its function in normal cell cytokinesis. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34737214      PMCID: PMC9056178          DOI: 10.1158/0008-5472.CAN-20-4218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  52 in total

1.  Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients.

Authors:  Masakazu Sano; Nobuyuki Genkai; Naoki Yajima; Naoto Tsuchiya; Junpei Homma; Ryuichi Tanaka; Toru Miki; Ryuya Yamanaka
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

Review 2.  Cytokinesis defects and cancer.

Authors:  Susanne M A Lens; René H Medema
Journal:  Nat Rev Cancer       Date:  2019-01       Impact factor: 60.716

3.  Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

Authors:  Verline Justilien; Syed A Ali; Lee Jamieson; Ning Yin; Adrienne D Cox; Channing J Der; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2017-01-19       Impact factor: 31.743

4.  Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients.

Authors:  Yi Jin; Yuhui Yu; Qinshu Shao; Yingyu Ma; Ruxuan Zhang; Haibo Yao; Yuan Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 5.  RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?

Authors:  Richard G Hodge; Antje Schaefer; Sarah V Howard; Channing J Der
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-08-25       Impact factor: 8.250

Review 6.  Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease.

Authors:  D R Cook; K L Rossman; C J Der
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

7.  Structure and regulation of human epithelial cell transforming 2 protein.

Authors:  Mengran Chen; Han Pan; Lingfei Sun; Peng Shi; Yikan Zhang; Le Li; Yuxing Huang; Jianhui Chen; Peng Jiang; Xianyang Fang; Congying Wu; Zhucheng Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-30       Impact factor: 11.205

8.  The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of Pre-rRNA processing factors.

Authors:  Lionel Tafforeau; Christiane Zorbas; Jean-Louis Langhendries; Sahra-Taylor Mullineux; Vassiliki Stamatopoulou; Romain Mullier; Ludivine Wacheul; Denis L J Lafontaine
Journal:  Mol Cell       Date:  2013-08-22       Impact factor: 17.970

9.  ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Authors:  Yoshihiko Murata; Yuko Minami; Reika Iwakawa; Jun Yokota; Shingo Usui; Koji Tsuta; Kouya Shiraishi; Shingo Sakashita; Kaishi Satomi; Tatsuo Iijima; Masayuki Noguchi
Journal:  Cancer Sci       Date:  2014-03-19       Impact factor: 6.716

10.  Zonation of Ribosomal DNA Transcription Defines a Stem Cell Hierarchy in Colorectal Cancer.

Authors:  Clara Morral; Jelena Stanisavljevic; Xavier Hernando-Momblona; Elisabetta Mereu; Adrián Álvarez-Varela; Carme Cortina; Diana Stork; Felipe Slebe; Gemma Turon; Gavin Whissell; Marta Sevillano; Anna Merlos-Suárez; Àngela Casanova-Martí; Catia Moutinho; Scott W Lowe; Lukas E Dow; Alberto Villanueva; Elena Sancho; Holger Heyn; Eduard Batlle
Journal:  Cell Stem Cell       Date:  2020-05-11       Impact factor: 24.633

View more
  1 in total

1.  ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer.

Authors:  Xiaoli Liu; Junhua Zhang; Shuang Ju; Lu Liu; Yu Sun; Lingyu Guo; Qianwei Zhen; Sai Han; Wei Lu; Youzhong Zhang
Journal:  Cancer Gene Ther       Date:  2022-09-02       Impact factor: 5.854

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.